On 15 April 2026, we celebrated the stock market debut of Syn2bio, a biotechnology company spun off from Synektik, which has been listed on the Warsaw Stock Exchange (WSE) for more than a decade. As PR adviser, NBS supported the demerger of Synektik and the separation of its research and development activities into Syn2bio from the very beginning. The company’s debut on the WSE marks the symbolic culmination of this process.
“Syn2bio’s debut on the Warsaw Stock Exchange is an important moment for the new company, but also a significant milestone in the history of the Synektik Group. Symbolically, it completes the process of dividing Synektik into two independent entities. We spun off the cardiotracer project — our flagship R&D project — to Syn2bio. The company’s task will now be to continue developing this innovative radiopharmaceutical for the diagnosis of heart disease and to prepare it for commercialization. The demerger opens up access for Syn2bio to new sources of financing, including grants and programmes dedicated to SMEs, which were no longer available to Synektik as a large enterprise. At the same time, Synektik, which has so far financed the work on the cardiac tracer, gains more room to further strengthen its profitability and develop its core business areas. We also believe that separating these two distinct business profiles will allow the market to assess the potential of each company more accurately,” – explains Cezary Kozanecki, founder and CEO of Synektik and CEO of Syn2bio.
As PR adviser, NBS Communications had the pleasure of supporting Synektik throughout the entire demerger process, which began more than a year ago, and was responsible for preparing and executing a comprehensive communications campaign. This included, among other things, support for Syn2bio’s public share offering addressed to Synektik shareholders.
“It was a unique transaction, rarely seen on the Polish market. This was neither a classic initial public offering (IPO) nor a transfer from NewConnect to the main market, but the WSE debut of a company spun off from another listed company. The project attracted considerable interest from both the media and investors. On the first day of trading, demand for Syn2bio shares was so strong that it proved impossible to balance the order book and determine the share price. The first transactions were concluded only on the second day, at a price significantly above the reference price. This debut shows that a well-thought-out demerger can be another important step in building value. We keep our fingers crossed for the continued success of both Synektik and Syn2bio,” comments Piotr Wojtaszek, CEO of NBS Communications.
